Companies: 10,795·Total market cap: $144.5T
Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTXNASDAQHealthcare● Active
$7.71
+$0.24(+3.21%)
Market Cap$337634076
P/E Ratio
52W High$13.67
52W Low$2.52
Overview

Kyverna Therapeutics, Inc. (KYTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KYTX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.28kytx eps ttm · kytx earnings per shareEarnings history
PE Ratio (TTM)kytx pe ratio ttm · kytx price to earningsPE Ratio deep dive
Revenue (TTM)0.00kytx revenue ttm · kytx annual revenueFull revenue history
Dividend YieldNo Dividenddoes kytx pay dividends · kytx dividend yieldDividend history
Shares Outstanding44.3Mkytx shares outstanding · kytx floatShares outstanding history
Next EarningsAug 11, 2026Est.kytx earnings date · kytx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
kyverna therapeutics, inc. revenue · kytx revenue 2025
FY 2025Net Income-$161.3M▼ 26.54% YoY
202320242025
kyverna therapeutics, inc. net income · kytx profit 2025
FY 2025EPS$-3.64▼ 9.31% YoY
202320242025
kytx eps · kyverna therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$156.4MEPS: $-3.28View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy4 analystsis kytx a buy · kytx analyst rating
Strong Buy
0
Buy
4
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$25.00Low
$7.71Current
$30.75Avg Target298.83% upside
$33.00High
kytx price target · kytx 12 month forecast

Total: 4 · Buy rate: 100.0%

The KYTX analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $30.75, representing +298.83% upside from the current price of $7.71.

Stock Performance

Full History
1D+1.87%
1W-2.93%
1M-18.61%
3M-6.05%
YTD-19.04%
1Y+120.58%
5Y-74.63%

About Kyverna Therapeutics, Inc.

CEOWarner Biddle
IPO DateFeb 9, 2024
Employees112
CountryUS

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the advancement of cell-based therapies to treat individuals suffering from autoimmune disorders. Its primar…

what is kyverna therapeutics, inc. · kytx stock overview · kyverna therapeutics, inc. company profile · who is kyverna therapeutics, inc. ceo · kytx NASDAQ · kyverna therapeutics, inc. headquarters · kyverna therapeutics, inc. business segments

About Stock Overview & Key Data

Kyverna Therapeutics, Inc. (KYTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 9, 2024. As of the latest trading session, KYTX stock price is $7.71, with a market capitalization of $337.6M. The stock has returned +120.58% over the past 12 months and -19.04% year-to-date.

According to 4 Wall Street analysts, the consensus rating for Kyverna Therapeutics, Inc. stock is Buy, with an average 12-month price target of $30.75. In fiscal year 2025, Kyverna Therapeutics, Inc. reported revenue of — and net income of -$161.3M. For detailed data — including Kyverna Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kyverna Therapeutics, Inc. (KYTX) stock price is $7.71. The stock is traded on NASDAQ under the ticker symbol KYTX. The 52-week range is $2.52 – $13.67.

KYTX stock priceKYTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice